Employing our mouse models differentially expressing GFI1, we were thus interested in evaluating the therapeutic potential of curcumin in a setting of MDS-AML patients expressing reduced GFI1 or GFI1-36N SNP variant. This evidence concerns the gene GFI1 and myelodysplastic syndrome.